Furthermore, combination treatment with JQ1 and the BCL2 inhibitors ABT-263 damaged the balance of Bim and Bcl-2, resulting in the release of the pro-apoptotic protein BIM in MYCN-amplified SCLC cell lines and exerted growth-inhibitory effects in MYCN-positive xenografts (Wang et al., 2017). Here, MYCN is linked to small cell lung carcinoma.